Nav: Home

Therapeutic and diagnostic functions of one antibody for pancreatic cancer

January 24, 2019

Osaka, Japan - Of all gastrointestinal cancers, pancreatic cancer is one of the most aggressive. Because of this, it has a very low 5-year survival rate of just 5% and a median survival time below 6 months. Additionally, treatment is difficult, with only surgery shown to provide a cure. However, the vast majority of patients have tumors that cannot be removed surgically or their cancer is too advanced or spread too far to be treatable.

Current chemotherapy for pancreatic cancer is ineffective long-term. Therefore, to improve the prognosis and as a novel treatment, Osaka University researchers identified a marker protein that could be used in molecular targeted therapy and companion diagnostics. Such a tool can determine how suitable a treatment is for a specific patient, enabling tailored therapy to be administered.

The team studied CKAP4, a plasma membrane protein that functions as a receptor for the secreted protein DKK1 and promotes tumorigenesis. They found that CKAP4 was released from pancreatic cancer cells in exosomes, which are tiny membranous sacs produced by tumor cells to communicate with each other. An advantage of secreted membranous proteins is that they are fairly simple to detect because of their accessibility, so two related techniques were developed to do just this.

"We generated anti-CKAP4 monoclonal antibodies that we used to develop ELISAs for the detection of CKAP4 released by tumors," says first author Hirokazu Kimura. "These were successfully able to measure CKAP4 protein in the serum of pancreatic cancer patients, and expression levels were shown to match those determined in the tumors themselves."

These same monoclonal antibodies had the added advantages of blocking signaling in pancreatic tumor cells and preventing them from proliferating and migrating in the laboratory. The team then analyzed the effects of the antibodies on mouse tumors that had developed from the transplantation of human pancreatic cancer cells. Some of the antibodies inhibited tumor growth and stopped the spread of tumors to the lymph nodes, thus crucially prolonging the life of the mice.

"Our work on developing monoclonal antibody preparations against pancreatic cancer offers the dual benefits of diagnosing and treating the disease," explains corresponding author Akira Kikuchi. "As a next step, we hope to develop screening methods for patients carrying the CKAP4 antigen biomarker who will benefit from therapeutic interventions using anti-CKAP4 antibodies."
-end-
The article, "CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy" was published in Clinical Cancer Research at DOI: https://doi.org/10.1158/1078-0432.CCR-18-2124.

Osaka University

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...